Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DTIL
SellHot AirPrecision BioSciences, Inc. · Healthcare · United States · $215M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Precision BioSciences, Inc. is a clinical-stage biotechnology company developing gene editing therapies using its proprietary ARCUS® platform. The company's focus includes allogeneic CAR T immunotherapies for cancer, in vivo gene editing for genetic diseases, and ex vivo gene editing for gene and cell therapy. Precision BioSciences' strength lies in its differentiated gene editing technology and its potential to address a wide range of therapeutic indications.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.1M | 48.7M | 68.7M | 34.3M | 10.9% | 45.1M | 13.5M | 8.9M | -49.1% |
| EPS | -5.46 | -2.58 | 0.33 | -3.56 | — | -1.32 | -3.87 | -1.86 | — |
| Shares | 25.8M | 25.8M | 25.8M | 24.1M | -6.6% | 27.6M | — | — | — |
| Debt | 25.0M | 31.3M | 30.0M | 28.8M | 4.9% | 28.1M | — | — | — |
| Equity | 60.4M | 18.9M | 56.4M | 92.2M | 15.1% | — | — | — | — |
| Op CF | -45.8M | -84.1M | -58.4M | -65.8M | — | -51.9M | — | — | — |
| Inv CF | -3.3M | 5.8M | -0.2M | -0.6M | — | — | — | — | — |
| Fin CF | 95.0M | 5.4M | 50.5M | 95.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DTIL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DTIL | Precision BioSciences, Inc.(you) | $215M | 28 | Sell |
| IMUX | Immunic, Inc. | $210M | 26 | Sell |
| ANTX | AN2 Therapeutics, Inc. | $211M | 35 | Sell |
| ACOG | Alpha Cognition Inc. Common Stock | $199M | 34 | Sell |
| NKTX | Nkarta, Inc. | $198M | 22 | Sell |
| WHWK | Whitehawk Therapeutics, Inc. | $263M | 32 | Sell |
| EQ | Equillium, Inc. | $152M | 27 | Sell |
| OKUR | OnKure Therapeutics, Inc. | $153M | 26 | Sell |
| PALI | Palisade Bio, Inc. | $349M | 29 | Sell |
| IKT | Inhibikase Therapeutics, Inc. | $336M | 31 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%